The field of PIK3CA mutations has recently garnered increasing interest, with the clinical results of the SOLAR1 trial showing an improvement in PFS with alpelisib (an α-selective PI3K inhibitor) in patients whose tumor presented a somatic PIK3CA mutation in one of the three mutational hotspots6. This evidence concerns the gene PIK3CA and neoplasm.